Global Liquid Biopsy Market Research Report- Forecast to 2022

Global Liquid Biopsy Market Research Report- Forecast to 2022

ID: MRFR/HC/0239-CRR | April, 2017 | Region: Global | 171 pages | Cooked Research Reports

Global Liquid Biopsy Market Information, by Biomarker Types (Circulating Tumor Cells (Ctcs), Circulating Tumor Dna (Ctdna), Extracellular Vesicles (Evs) and Other Biomarker (Circulating Rna And Proteins), by Application (Cancer Therapeutic Application, Reproductive Health, Other Therapeutic Application), by Sample (Blood Sample, Urine Sample, Other) And End User (Hospitals and Laboratories, Academic And Research Centers, Other End Users) - Forecast to 2022



Market Synopsis of Global Liquid Biopsy market:


Market Scenario:


A liquid biopsy is a largely non-invasive, sampling and analysis of liquid state biological tissue for diagnostic and monitoring diseases such as cancer. Liquid biopsy is the direct clinical application of two advances in medical science namely human genome sequencing and rising sensitivity of detecting techniques and assays.


The global Liquid Biopsy market is currently valued at $ 3950 million and will reach $ 17,372.28 million growing at a CAGR of 28%. The growth factors responsible for this explosive growth are liquid biopsy is a comparatively painless and non-invasive technique which provides early real time high precision detection of diseases which could be used for monitoring and designing effective treatment strategies based on the real time molecular assessment for the progression of the disease. Other factors driving the liquid biopsy market are lifestyle changes and environmental factors such as rising investment in research and development and collaborations between companies and public organizations, rise in population particularly geriatric population, rising expenditure on health etc. The technique also has other advantages over traditional tissue biopsy such as potential applications to cardiovascular diseases, autoimmune diseases etc.


The restraints include the prohibitive costs associated with liquid biopsy and the differential awareness and availability between developing and the developed world. Also not all cancer patients benefit from early detection as some cancers such as brain cancer and prostate cancer may lie dormant for many years. Further liquid biopsy is not all non-invasive as can be seen in case of using spinal fluid as sample.


Global Liquid Biopsy Market, by Region 2015 (% share) 


 Liquid Biopsy Market Image


Intended Audience



  • Global Liquid Biopsy test kit manufacturers

  • Global Liquid Biopsy test kit suppliers

  • Research and development Laboratories

  • Market Research and Consulting Service Providers


Key findings



  • Circulating tumor cells (CTCs) segment dominates both in terms of market share as well as revenues, contributing approx. 55.48% of the revenue share of the liquid biopsy market.

  • On the basis of the therapeutic application, the segment for Cancer will reflect the highest growth potential, with over 82.83% of the market share by revenues. However, the urine sample segment is anticipated to witness noticeable growth.

  • The market for liquid biopsy is dominated by North America and Europe and this trend will continue. Asia-Pacific market is the fastest growing market and is expected to grow at a CAGR of 29.7% during forecasted period



Key Players for Global Liquid Biopsy market:


Guardant Health, Inc., Trovagene, Inc., RainDance Technologies, Inc., Agena Bioscience Inc. Inc., Admera Health, Biocept, Inc., Circulogene Theranostics,  Inivata Ltd.,  SAGA Diagnostics AB,  Exosome Diagnostics and others.



Segments:
Global Liquid Biopsy market has been segmented on the basis of biomarker type which comprises of circulating tumor cells (Ctcs), circulating tumor DNA (Ctdna), extracellular vesicles (Evs) and other biomarker. On the basis of application; market is segmented into cancer therapeutic application, reproductive health, and other therapeutic application. On the basis of sample; market is segmented into blood, urine and others. On the basis of end-users; market is segmented into hospitals and laboratories, academic and research centers and others.


Regional Analysis of Global Liquid Biopsy market:


Globally North America is the largest market for Global Liquid Biopsy market. Europe is the second-largest market for Global Liquid Biopsy market. However the developing regions market particularly Asia Pacific will be the fastest growing and will be the key to the future. North America accounted for the largest market share of 37.95% in 2016 accounting for a market value of 1,499.10 million in  2016. Asia pacific is the fastest growing market which is growing at a CAGR of 28.8%.



The report for
Global Liquid Biopsy market of Market Research Future comprises extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.

License

Single User Enterprise User (Buy Premium Reports Chapterwise)
TABLE OF CONTENTS

2.1 Scope of Study

2.2 Research Objective

2.3 Assumptions & Limitations

2.3.1 Assumptions

2.3.2 Limitations

2.4 Market Structure

3.1 Research Process

3.2 Primary Research

3.3 Secondary Research

4.1 Introduction

4.2 Drivers

4.2.1 Comparatively painless and non-invasive technique

4.2.2 Early real time high precision detection of diseases

4.2.3 Useful for designing effective treatment strategies based on the real time molecular assessment for the progression of the disease

4.2.4 Rise in cases of cancer and other diseases

4.2.5 Lifestyle changes and environmental factors

4.2.6 Other advantages over other techniques

4.2.7 The recent technological advancements has increased the appeal of liquid biopsy

4.2.8 Transferability of liquid biopsy

4.2.9 Rising investment in research and development and collaborations between companies and public organizations

4.2.10 Greater focus on venture capital

4.2.11 Demographical factors

4.3 Restraints

4.3.1 Prohibitive costs associated with liquid biopsy

4.3.2 Lower sensitivity for certain biomarkers

4.3.3 Not all cancers patients benefit from early detection

4.3.4 Liquid biopsy is not all non-invasive

4.3.5 Differential awareness and availability between developing and developed world

4.3.6 Issues in venture capital, startups and collaborations

4.4 Opportunities

4.4.1 Growing collaboration between companies has become the entrance gateway for new firms

4.4.2 Funding from public organizations is a good strategy to reduce development costs

4.4.3 Rise in research and development investment

4.4.4 Developing economies provide an unserved market for liquid biopsy

4.4.5 Growing trend of start-ups and venture investment in the field of liquid biopsy

4.5 Challenges

4.5.1 Information and interest gap between the investors and the developers

4.5.2 Lack of trained professionals in developing regions

4.5.3 Lack of standardization and transparency

5.1 Porter’s Five Force Analysis

5.1.1 Bargaining Power of Buyer

5.1.2 Bargaining Power of Supplier

5.1.3 Threat from substitute

5.1.4 Threat from a New Entrant

5.1.5 Intensity of Competitive Rivalry

5.2 Value Chain Analysis

5.2.1 Device Manufacturers

5.2.2 Software developers

5.2.3 Reagent and accessory suppliers

5.2.4 Healthcare providers

5.2.5 Patients

6.1 Introduction

6.2 Circulating Tumor Cells (CTCs)

6.3 Circulating Tumour DNA (CtDNA)

6.4 Extracellular Vesicles (EVs)

6.5 Other biomarker (circulating RNA and proteins)

7.1 Introduction

7.2 Cancer

7.3 Reproductive health

7.4 Other therapeutic application

8.1 Introduction

8.2 Blood Sample

8.3 Urine sample

8.4 Other sample

9.1 Introduction

9.2 Hospitals and Laboratories

9.3 Academic and Research Centres

9.4 Other end users 56

10.1 Introduction

10.2 North America

10.2.1 US

10.2.2 CANADA

10.3 Europe

10.3.1 Germany

10.3.2 France

10.3.3 U.K.

10.3.4 Italy

10.3.5 Spain

10.3.6 Rest of Europe

10.4 Asia-Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 Korea

10.4.6 Rest of Asia Pacific

10.5 Middle East and Africa

10.5.1 UAE

10.5.2 Saudi Arabia

10.5.3 Egypt

10.5.4 Rest of Middle East and Africa

11.1 Guardant Health, Inc

11.1.1 Company Overview

11.1.2 Product/Business Segment Overview

11.1.3 Financial Overview

11.1.4 Key Development

11.1.5 SWOT Analysis

11.2 Trovagene, Inc

11.2.1 Company Overview

11.2.2 Product/Business Segment Overview

11.2.3 Financial Overview

11.2.4 SWOT Analysis

11.3 RainDance Technologies, Inc.

11.3.1 Company Overview

11.3.2 Product/Business Segment Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 Agena Bioscience Inc. Inc.

11.4.1 Company Overview

11.4.2 Product/Business Segment Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 Admera Health

11.5.1 Company Overview

11.5.2 Product/Business Segment Overview

11.5.3 Financial Overview

11.5.4 Key Development

11.5.5 SWOT Analysis

11.6 Biocept, Inc.

11.6.1 Company Overview

11.6.2 Product/Business Segment Overview

11.6.3 Financial Overview

11.6.4 Key Development

11.7 Circulogene Theranostics

11.7.1 Company Overview

11.7.2 Product/Business Segment Overview

11.7.3 Financial Overview

11.7.4 Key Development

11.8 Inivata Ltd

11.8.1 Company Overview

11.8.2 Product/Business Segment Overview

11.8.3 Financial Overview

11.8.4 Key Development

11.9 SAGA Diagnostics AB

11.9.1 Company Overview

11.9.2 Product/Business Segment Overview

11.9.3 Financial Overview

11.9.4 Key Development

11.10 Exosome Diagnostics

11.10.1 Company Overview

11.10.2 Product/Business Segment Overview

11.10.3 Financial Overview

11.10.4 Key Development